P. Paradiso

发表

Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus.

S. Levine, R. Klaiber-Franco, P. Paradiso, 1987, The Journal of general virology.

P. Paradiso, R. Kohberger, 1999 .

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

G. Siber, P. Paradiso, William P. Hausdorff, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 in United States Infants

M. Rennels, K. Reisinger, K. Edwards, 1998, Pediatrics.

Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV).

B. Murphy, G. Prince, P. Collins, 1991, Vaccine.

Recent progress in the development of vaccines for infants and children.

P. Paradiso, E. McIntosh, 2003, Vaccine.

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

G. Siber, P. Paradiso, William P. Hausdorff, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.

S. Black, G. Siber, B. Fireman, 1999, The Pediatric infectious disease journal.

Pneumococcal Conjugate Vaccine for Adults: A New Paradigm

P. Paradiso, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.

T. File, J. Graepel, P. Paradiso, 2013, The Journal of infectious diseases.

A transmembrane relationship between fibronectin and vinculin (130 kd protein): Serum modulation in normal and transformed hamster fibroblasts

I. Singer, P. Paradiso, 1981, Cell.

Essential criteria for evaluation of pneumococcal conjugate vaccine candidates.

P. Paradiso, 2009, Vaccine.

Maternal immunization: the influence of liability issues on vaccine development.

P. Paradiso, Peter R. Paradiso, 2001, Vaccine.

Safety and immunogenicity of heptavalent pneumococcal CRM 197 conjugate vaccine in infants and toddlers

S. Black, G. Siber, B. Fireman, 2022 .

Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children

G. Siber, P. Paradiso, William P. Hausdorff, 2001, The Lancet.

Pneumococcal conjugate vaccine use in adults

R. Isturiz, P. Paradiso, H. Sings, 2016, Expert review of vaccines.

Pneumococcal conjugate vaccine in adults: Let’s see what happens

P. Paradiso, 2016, Human vaccines & immunotherapeutics.

Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe

P. Paradiso, B. Fritzell, R. Reinert, 2010, Expert review of vaccines.

Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.

A. Gurtman, W. Gruber, A. Pollard, 2013, Vaccine.

Alkaline phosphatase fusions to the respiratory syncytial virus F protein as an approach to analyze its membrane topology.

A. Martín-Gallardo, A. Anilionis, P. Paradiso, 1989, DNA.

Combination Vaccines for Diphtheria, Tetanus, Pertussis, and Haemophilus influenzae Type b

P. Paradiso, 1995, Annals of the New York Academy of Sciences.

Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants.

E. Rothstein, K. Reisinger, H. Bernstein, 1993, Pediatrics.

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.

S. Madhi, K. O'Brien, G. Siber, 2007, Vaccine.

Glycoconjugate vaccines: future combinations.

A. Lindberg, P. Paradiso, 1996, Developments in biological standardization.

The future of polio immunization in the United States: are we ready for change?

P. Paradiso, 1996, The Pediatric infectious disease journal.

Conjugate Vaccines for Streptococcus pneumoniae

P. Paradiso, 1999 .

Mapping of the amino terminus of the H-1 parvovirus major capsid protein

K. Williams, P. Paradiso, R. Costantino, 1984, Journal of virology.

Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement.

P. Paradiso, D. Hogerman, S. Hildreth, 1994, Vaccine.

Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins.

J. Schlesinger, E. Walsh, C. Hall, 1989, The Journal of general virology.

Infectious process of the parvovirus H-1: correlation of protein content, particle density, and viral infectivity

P. Paradiso, 1981, Journal of virology.

Reassessing the 1 + 1 pneumococcal conjugate vaccine schedule.

B. Gessner, R. Isturiz, P. Paradiso, 2018, The Lancet. Infectious diseases.

Interprotein disulfide bonding between F and G glycoproteins of human respiratory syncytial virus

P. Paradiso, S. Hildreth, R. Arumugham, 2005, Archives of Virology.

Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants.

M. Rennels, K. Reisinger, K. Edwards, 2001, The Pediatric infectious disease journal.

Challenges in estimating efficacy against pneumococcal pneumonia in children.

P. Paradiso, Kimberly J. Center, 2012, The Pediatric infectious disease journal.

Immunology of combining CRM(197) conjugates for Streptococcus pneumoniae, Neisseria meningitis and Haemophilus influenzae in Chilean infants.

M. Levine, I. Chang, P. Paradiso, 2009, Vaccine.

The immunogenicity of Haemophilus influenzae type b conjugate (HbOC) vaccine in human immunodeficiency virus‐infected and uninfected infants

P. Paradiso, J. King, J. Farley, 1995, The Pediatric infectious disease journal.

Relevance of HTLV-1 proviral load in asymptomatic and symptomatic patients living in endemic and non-endemic areas of Argentina

M. B. Bouzas, A. Mangano, P. Paradiso, 2019, PloS one.

Parvovirus replication in normal and transformed human cells correlates with the nuclear translocation of the early protein NS1

P. Paradiso, S. Rhode, 1989, Journal of virology.

Canine parvovirus: a biochemical and ultrastructural characterization.

I. Singer, P. Paradiso, S. Rhode, 1982, The Journal of general virology.

Analysis of the protein-protein interactions in the parvovirus H-1 capsid

P. Paradiso, 1983, Journal of virology.

Photochemical cross-linking of protein . nucleic acid complexes. The attachment of the fd gene 5 protein to fd DNA.

W. Konigsberg, Y. Nakashima, P. Paradiso, 1979, The Journal of biological chemistry.

Correlation between distribution of cytoskeletal proteins and release of alkaline phosphatase-rich vesicles by epiphyseal chondrocytes in primary culture.

J. Hale, J. Chin, R. Wuthier, 1983, Cell motility.

Fatty acid acylation of the fusion glycoprotein of human respiratory syncytial virus.

S. Doyle, P. Paradiso, S. Hildreth, 1989, The Journal of biological chemistry.

Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium.

A. Martín-Gallardo, P. Collins, S. Doyle, 1993, The Journal of general virology.

Identification of multiple forms of the noncapsid parvovirus protein NCVP1 in H-1 parvovirus-infected cells

P. Paradiso, 1984, Journal of virology.

Parvovirus genome: nucleotide sequence of H-1 and mapping of its genes by hybrid-arrested translation

P. Paradiso, S. Rhode, 1983, Journal of virology.

Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.

R. Chanock, A. Sotnikov, L. Lawrence, 1989, Vaccine.

Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.

P. Paradiso, D. Hogerman, S. Hildreth, 1993, The Journal of infectious diseases.

Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at 3-6 months after immunization.

P. Paradiso, W. Castleman, D. Brownstein, 1993, Vaccine.

Immunogen-induced enhanced pulmonary histopathology in the RSV cotton rat model.

P. Paradiso, W. Castleman, D. Brownstein, 1993, Vaccine.

Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.

P. Paradiso, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee.

J. P. Davis, Bruce Gellin, William Schaffner, 2003, JAMA.

Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old.

P. Paradiso, D. Hogerman, J. Oren, 1994, The Pediatric infectious disease journal.

Evidence that the fusion protein of respiratory syncytial virus exists as a dimer in its native form

P. Paradiso, S. Hildreth, R. Arumugham, 2005, Archives of Virology.

Photochemical cross-linking of the gene 5 protein.fd DNA complex from fd-infected cells.

W. Konigsberg, P. Paradiso, 1982, The Journal of biological chemistry.

Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection.

P. Piedra, J. Kasel, P. Paradiso, 1995, Vaccine.

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia.

E. Simões, P. Paradiso, J. Groothuis, 1998, The Journal of infectious diseases.

Comment on "Serotypes and susceptibility of Streptococcus pneumoniae strains isolated from children in Mexico".

P. Paradiso, G. Rodgers, H. Bierschwale, 2009, Salud publica de Mexico.

Short communication: Emergence of novel A/G recombinant HIV-1 strains in Argentina.

C. Terrones, A. Mangano, R. Bologna, 2015, AIDS research and human retroviruses.

Expression of the F glycoprotein gene from human respiratory syncytial virus in Escherichia coli: mapping of a fusion inhibiting epitope.

A. Martín-Gallardo, P. Collins, P. Paradiso, 1991, Virology.

Parvovirus Replication inNormalandTransformed HumanCells Correlates withtheNuclear Translocation oftheEarlyProtein NS1

P. Paradiso, S. Rhode, 1989 .

A transmembrane relationship between fibronectin and vinculin (130 kd protein): Serum modulation in normal and transformed hamster fibroblasts

I. Singer, P. Paradiso, 1981, Cell.

Essential criteria for evaluation of pneumococcal conjugate vaccine candidates.

P. Paradiso, 2009, Vaccine.